Lorena de la Mora

2.7k total citations
32 papers, 239 citations indexed

About

Lorena de la Mora is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Lorena de la Mora has authored 32 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 18 papers in Epidemiology and 9 papers in Virology. Recurrent topics in Lorena de la Mora's work include HIV/AIDS Research and Interventions (17 papers), HIV/AIDS drug development and treatment (13 papers) and HIV Research and Treatment (9 papers). Lorena de la Mora is often cited by papers focused on HIV/AIDS Research and Interventions (17 papers), HIV/AIDS drug development and treatment (13 papers) and HIV Research and Treatment (9 papers). Lorena de la Mora collaborates with scholars based in Spain, United Kingdom and United States. Lorena de la Mora's co-authors include Juan Ambrosioni, Josep Mallolas, Alexy Inciarte, Berta Torres, Montserrat Laguno, Maria Martínez‐Rebollar, Estebán Martínez, Elisa de Lazzari, José Luís Blanco and Ana González-Cordón and has published in prestigious journals such as AIDS, Journal of Antimicrobial Chemotherapy and BMC Public Health.

In The Last Decade

Lorena de la Mora

25 papers receiving 234 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lorena de la Mora Spain	9	182	71	66	48	28	32	239
Alexy Inciarte Spain	11	275 1.5×	122 1.7×	127 1.9×	84 1.8×	31 1.1×	39	378
Xi He China	8	217 1.2×	92 1.3×	25 0.4×	17 0.4×	15 0.5×	14	278
Tabitha Mahungu United Kingdom	10	169 0.9×	82 1.2×	46 0.7×	25 0.5×	8 0.3×	18	254
Yanhan Shen United States	8	123 0.7×	31 0.4×	58 0.9×	45 0.9×	30 1.1×	25	218
Rachael Lazar United States	8	186 1.0×	80 1.1×	23 0.3×	29 0.6×	27 1.0×	15	231
Marisol Martínez United States	7	151 0.8×	107 1.5×	35 0.5×	52 1.1×	41 1.5×	20	251
Noga Shalev United States	7	125 0.7×	44 0.6×	21 0.3×	17 0.4×	29 1.0×	13	160
Carol-Ann Swain United States	6	232 1.3×	69 1.0×	14 0.2×	17 0.4×	60 2.1×	10	276
Zhongbao Zuo China	7	328 1.8×	68 1.0×	96 1.5×	8 0.2×	13 0.5×	16	385
Iain Reeves United Kingdom	12	173 1.0×	220 3.1×	34 0.5×	27 0.6×	4 0.1×	29	357

Countries citing papers authored by Lorena de la Mora

Since Specialization

Citations

This map shows the geographic impact of Lorena de la Mora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorena de la Mora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorena de la Mora more than expected).

Fields of papers citing papers by Lorena de la Mora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorena de la Mora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorena de la Mora. The network helps show where Lorena de la Mora may publish in the future.

Co-authorship network of co-authors of Lorena de la Mora

This figure shows the co-authorship network connecting the top 25 collaborators of Lorena de la Mora. A scholar is included among the top collaborators of Lorena de la Mora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorena de la Mora. Lorena de la Mora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alonso, Rodrigo, Iván Chivite, Lorena de la Mora, et al.. (2025). The Role of Protease Inhibitors in HIV Treatment: Who Still Needs Them in 2025?. Infectious Diseases and Therapy. 14(11). 2551–2563.

Mora, Lorena de la, Josep Mallolas, & Juan Ambrosioni. (2024). Epidemiología, tratamiento y pronóstico de la infección VIH en 2024: revisión práctica. Medicina Clínica. 162(11). 535–541. 5 indexed citations

Laguno, Montserrat, Elisa de Lazzari, Alexy Inciarte, et al.. (2024). Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV. HIV Medicine. 25(12). 1308–1324. 1 indexed citations

Nomah, Daniel K., Andreu Bruguera, Yesika Díaz, et al.. (2024). Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998–2020. Open Forum Infectious Diseases. 11(4). ofae132–ofae132. 4 indexed citations

Chivite, Iván, Elisa de Lazzari, Soodabeh Navadeh, et al.. (2024). Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy. 79(8). 1775–1783. 9 indexed citations

Mora, Lorena de la, Josep Mallolas, & Juan Ambrosioni. (2024). Epidemiology, treatment and prognosis of HIV infection in 2024: A practical review. Medicina Clínica (English Edition). 162(11). 535–541. 4 indexed citations

Téllez, Adrián, Sara Fernández, Gemma Martínez‐Nadal, et al.. (2024). Epidemiological changes and outcomes of people living with HIV admitted to the intensive care unit: a 14-year retrospective study. Infection. 53(2). 583–592. 1 indexed citations

Lazzari, Elisa de, Lorena de la Mora, Alexy Inciarte, et al.. (2023). Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study. Journal of Antimicrobial Chemotherapy. 78(8). 1955–1962. 4 indexed citations

Revollo, Boris, Laura Viñuela, Lorena de la Mora, et al.. (2022). Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. Journal of Antimicrobial Chemotherapy. 77(6). 1738–1740. 12 indexed citations

10.

Ugarte, Ainoa, Lorena de la Mora, Maria Martínez‐Rebollar, et al.. (2022). Evolution of Risk Behaviors, Sexually Transmitted Infections and PrEP Care Continuum in a Hospital-Based PrEP Program in Barcelona, Spain: A Descriptive Study of the First 2 Years’ Experience. Infectious Diseases and Therapy. 12(2). 425–442. 3 indexed citations

11.

Mora, Lorena de la, Ainoa Ugarte, Maria Martínez‐Rebollar, et al.. (2022). Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life—Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain. AIDS and Behavior. 26(12). 4055–4062. 10 indexed citations

12.

Mora, Lorena de la, Maria Martínez‐Rebollar, Elisa de Lazzari, et al.. (2022). Do ART and Chemsex Drugs Get Along? Potential Drug–Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study. Infectious Diseases and Therapy. 11(6). 2111–2124. 8 indexed citations

13.

Martínez‐Rebollar, Maria, Lorena de la Mora, Elisa de Lazzari, et al.. (2021). Impact of Sexualized Substance Use and Other Risk Practices on HCV Microelimination in gbMSM Living with HIV: Urgent Need for Targeted Strategies. Results of a Retrospective Cohort Study. Infectious Diseases and Therapy. 10(3). 1253–1266. 7 indexed citations

14.

Matulionytė, Raimonda, et al.. (2021). Increased integrated testing for HIV, hepatitis C and sexually transmitted infections in health care facilities: results from the INTEGRATE Joint Action pilots in Lithuania, Romania and Spain. BMC Infectious Diseases. 21(S2). 845–845. 7 indexed citations

15.

Ugarte, Ainoa, Lorena de la Mora, Maria Martínez‐Rebollar, Josep Mallolas, & Montserrat Laguno. (2021). An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide–induced cholestasis. Antiviral Therapy. 26(1-2). 9–12.

16.

Laguno, Montserrat, Ainoa Ugarte, Maria Martínez‐Rebollar, et al.. (2021). Experiencia de un programa de profilaxis preexposición en una unidad de virus de la inmunodeficiencia humana hospitalaria. Descripción del perfil basal del usuario e identificación de oportunidades de mejora. Enfermedades Infecciosas y Microbiología Clínica. 41(1). 24–28. 2 indexed citations

17.

Laguno, Montserrat, Maria Martínez‐Rebollar, Elisa de Lazzari, et al.. (2021). Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. Clinical Microbiology and Infection. 28(4). 610.e1–610.e7. 5 indexed citations

18.

Laguno, Montserrat, Beatriz Álvarez, Maria Martínez‐Rebollar, et al.. (2020). Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis. Gastroenterología y Hepatología. 44(3). 191–197. 1 indexed citations

19.

Mora, Lorena de la, Félix Alegre, J. Rifón, Pablo Martí Ciriquián, & J.I. Herrero. (2018). Treatment of graft-versus-host disease with mesenchymal cells as a complication of a liver transplantation. Revista Española de Enfermedades Digestivas. 110(11). 734–736. 2 indexed citations

20.

Lama, Carmen, Emilio Ramos, Joan Figueras, et al.. (2002). Causes of mortality after liver transplantation: period of main incidence. Transplantation Proceedings. 34(1). 287–289. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact